News

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...
USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...
The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...
Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...
The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...
DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ ...
International firms are also looking to partner with Chinese counterparts at earlier stages to co-develop drugs – such as ...
AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.
AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of manufacturing and R&D projects planned over the next five years.
British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some credit due to its tariff policy and Presiden… ...
In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to build its largest drug manufacturing facility in the world somewhere in ...